Abstract: Disclosed are a polyethylene glycol conjugate drug, and a preparation method therefor and the use thereof. Specifically, the present invention relates to a polyethylene glycol conjugate drug represented by formula A or a pharmaceutically acceptable salt thereof, a method for preparing the polyethylene glycol conjugate drug or the pharmaceutically acceptable salt thereof, an intermediate for preparing the polyethylene glycol conjugate drug or the pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the polyethylene glycol conjugate drug or the pharmaceutically acceptable salt thereof, and the use of the polyethylene glycol conjugate drug or the pharmaceutically acceptable salt thereof in the preparation of a drug.

Abstract: Embodiments of the present disclosure are directed to a display panel and a display device. A width of the fan-out wire positioned at the outer side is increased such that the impedance of the outer fan-out wire could be reduced. Furthermore, the second part of the second fan-out wire is bended in a direction away from the display region. This means that the second part only occupies the right/left redundant space and thus the second fan-out wire consumes less space of the lower side frame and the width of the fan-out region decreases. The present disclosure could achieve both comparatively low impedance of the fan-out wire and a narrow side frame.

Abstract: Solid forms of 4-(5-(4-fluorophenyl)-6-(tetrahydro-2H-pyran-4-yl)-1,5-dihydropyrrolo[2,3-f]indazol-7-yl)benzoic acid (Compound 1) capable of modulating alpha-1 antitrypsin (AAT) activity and methods of treating alpha-1 antitrypsin deficiency (AATD) by administering one or more such forms, and methods of using and preparing the same for treatment of alpha-1 antitrypsin deficiency (AATD).

Abstract: The disclosure provides at least one entity chosen from compounds of formula (I), solid state forms of the same, compositions comprising the same, and methods of using the same, including use in treating focal segmental glomerulosclerosis (FSGS) and/or non-diabetic kidney disease (NDKD).

Abstract: The disclosure provides a compound of Formula (I), including deuterated derivatives, pharmaceutically acceptable salts, and solvates thereof, solid state forms of those compounds, compositions comprising those compounds and solid forms, and methods of using the same, including use in treating focal segmental glomerulosclerosis (FSGS) and/or non-diabetic kidney disease (NDKD).

Abstract: The present invention discloses a muted key module, an electronic device and an implementation method. The key module includes a switch member, a triggering mechanism and a supporting member, wherein the triggering mechanism is arranged corresponding to the switch member. The triggering mechanism can be moved along the contacting and separating directions of the switch member, thus to realize an ON or OFF operation of the switch member. A muting layer is arranged between the switch member and the supporting member. In the present invention, the muting layer is arranged between the switch member and the supporting member, so the impact force the between the triggering mechanism and the switch member can be cushioned by the muting layer, thereby reducing the noise produced when the key is pressed, thus to improve the quality of the final product as a whole.

Abstract: The disclosure provides at least one entity chosen from compounds of formula (I), solid state forms of the same, compositions comprising the same, and methods of using the same, including use in treating focal segmental glomeulosclerosis (FSGS) and/or non-diabetic kidney disease (NDKD).

Abstract: Polymorph Forms M, H, P, X, and ZA of Compound (1) represented by the following structural formula: are described. A method of preparing polymorph Form M of Compound (1) includes stirring a mixture of Compound (1) and a solvent system that includes isopropanol, ethyl acetate, n-butyl acetate, methyl acetate, acetone, 2-butanone (methylethylketone (MEK)), or heptane, or a combination thereof at a temperature in a range of 10° C. to 47° C. to form From M of Compound (1). A method of preparing polymorph Form H of Compound (1) includes stirring a solution of Compound (1) at a temperature in a range of 48° C. to 70° C. to form Form H of Compound (1). A method of preparing polymorph Form P of Compound (1) includes stirring a mixture of Compound (1) and a solvent system that includes a solvent selected from the group consisting of dichloromethane and tetrahydrofuran (THF), and a mixture thereof at room temperature to form Form P of Compound (1).

Abstract: The present invention provides methods for performing dynamic nuclear polarization using biradicals with a structure of formula (I) as described herein. In general, the methods involve (a) providing a frozen sample in a magnetic field, wherein the frozen sample includes a biradical of formula (I) and an analyte with at least one spin half nucleus; (b) polarizing the at least one spin half nucleus of the analyte by irradiating the frozen sample with radiation having a frequency that excites electron spin transitions in the biradical; (c) optionally melting the sample to produce a molten sample; and (d) detecting nuclear spin transitions in the at least one spin half nucleus of the analyte in the frozen or molten sample. The present invention also provides biradicals with a structure of formula (I) with the proviso that Q1 and Q2 are different when X1 and X2 are —O—. The present invention also provides methods for making biradicals with a structure of formula (IA) as described herein.

Abstract: In one aspect, the present invention provides a method for enhancing the sensitivity of liquid-state NMR or MRI experiments. In general, the method involves providing a frozen sample in a magnetic field, wherein the frozen sample includes a polarizing agent with at least one unpaired electron and an analyte with at least one spin half nucleus; polarizing the at least one spin half nucleus of the analyte by irradiating the frozen sample with radiation having a frequency that excites electron spin transitions in the at least one unpaired electron of the polarizing agent; melting the frozen sample to produce a molten sample; and (d) detecting nuclear spin transitions in the at least one spin half nucleus of the analyte in the molten sample. In certain embodiments, the methods further comprise a step of freezing a sample in a magnetic field to provide the frozen sample in a magnetic field.

Abstract: The present invention provides methods for performing dynamic nuclear polarization using biradicals with a structure of formula (I) as described herein. In general, the methods involve (a) providing a frozen sample in a magnetic field, wherein the frozen sample includes a biradical of formula (I) and an analyte with at least one spin half nucleus; (b) polarizing the at least one spin half nucleus of the analyte by irradiating the frozen sample with radiation having a frequency that excites electron spin transitions in the biradical; (c) optionally melting the sample to produce a molten sample; and (d) detecting nuclear spin transitions in the at least one spin half nucleus of the analyte in the frozen or molten sample. The present invention also provides biradicals with a structure of formula (I) with the proviso that Q1 and Q2 are different when X1 and X2 are —O—. The present invention also provides methods for making biradicals with a structure of formula (IA) as described herein.

Abstract: We describe polarizing agents for use in enhancing NMR and MRI signals via dynamic nuclear polarization (DNP). The polarizing agents include two or more paramagnetic centers, preferably two paramagnetic centers. In a preferred embodiment, the polarizing agent comprises two nitroxide radicals tethered by a polyethylene glycol chain of variable length. Signal enhancements of up to 175 have been achieved in comparison with factors of ˜45 at similar concentrations of monomeric radical such as TEMPO.

Abstract: We describe polarizing agents for use in enhancing NMR and MRI signals via dynamic nuclear polarization (DNP). The polarizing agents include two or more paramagnetic centers, preferably two paramagnetic centers. In a preferred embodiment, the polarizing agent comprises two nitroxide radicals tethered by a polyethylene glycol chain of variable length. Signal enhancements of up to 175 have been achieved in comparison with factors of ˜45 at similar concentrations of monomeric radical such as TEMPO.